Affymetrix Inc. has announced the publication of the MicroArray Quality Control (MAQC) study, a collaborative effort led by the FDA that included 137 scientists from private and public sector ...

Affymetrix Inc. and Partners HealthCare announced that they have extended their translational research collaboration with a new Contract Array Manufacturing (CAM) supply agreement, enabling Partners ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that the Wellcome Trust Sanger Institute has developed a catalog of structural genomic changes in almost 800 cancer ...

SANTA CLARA, Calif. & PARIS--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ: AFFX) and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell ...

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

The new Korean Association Resource program will analyze 13,000 samples to validate previous results and for new discovery. The Republic of Korea’s National Institute of Health (KNIH) and Center for ...

Affymetrix Inc. (Nasdaq:AFFX) and Baylor College of Medicine announced today that Baylor has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering comparative genomic ...

Initial focus will be on tools to help cancer diagnosis. Affymetrix and Ipsogen signed a Powered by Affymetrix™ (PbA) agreement. With this transaction, Ipsogen gains nonexclusive access to Affymetrix ...

India's Avesthagen has inked a deal to use Affymetrix's microarray technology in a genetic study involving 60,000 Parsi. The Avestagenome Project is studying the genetic foundation behind longevity.

SANTA CLARA, Calif., BERLIN and SEATTLE, June 27, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, ...

What: Kevin M. King, President and Chief Executive Officer of Affymetrix, Inc. (AFFX), will preside over the Opening Bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast ...

An English Court of Appeals decision in November held that Affymetrix (Santa Clara, CA) has a valid license to critical DNA microarray technology developed by Oxford Gene Technology (OGT; Oxford, UK).